FIBROBIOLOGICS INC

Insider option purchases at FibroBiologics signal executive confidence amid a steep decline, offering clues for investors to watch clinical milestones.

Insider buying at FibroBiologics signals confidence in a new patent and could signal a future rebound for the company’s stock.

CEO Pete O’Heeron’s bulk buying after FibroBiologics wins an osteoporosis patent signals strong insider confidence and potential upside for investors, but watch for clinical milestones.

Insight: Fibrobiologics CFO buys 70k shares at $0.41, signaling steady insider confidence amid a volatile market, hinting at long‑term growth potential.